Vitamin D is used in the treatment of 8+ health problems, raising levels somewhat

Vitamin D Use by Health Problem: Where a Majority of Patients Take It, and Who Decides

Claude Opus Nov 2026

Summary table

Health problem Dose range % of patients % of which by patients % of which prescribed by doctor Refs
Chronic hypoparathyroidism Calcitriol 0.25–2 µg/day (often split); alfacalcidol about 2× calcitriol dose; sometimes D2/D3 90.7% on calcitriol or alfacalcidol (PARADIGHM registry, 11 countries, to 2022) About 0% for active forms (estimate: prescription-only drugs); self-use of D3 not reported About 100% for active forms (estimate: prescription-only) PARADIGHM HRQoL 2024; Italy real-world data; Treatment options review[1][2]
Hemodialysis / secondary hyperparathyroidism Calcitriol about 0.25–1 µg/day oral; alfacalcidol mean 0.25 µg/day; IV paricalcitol/doxercalciferol 55% active vitamin D (DOPPS, 21 countries, 2005–2018); US 66% (2005–06); US 83.9% any form (2008); Europe 48% (COSMOS) Not reported; about 0% for active forms (estimate) About 100% for active forms (estimate: given or prescribed by the dialysis unit) DOPPS JBMR 2023; Landmark analysis 2018; US IV trends 2012[3][4][5]
Multiple sclerosis Mostly 2,000–5,000 IU/day D3 65.8% (US survey, 2011); 74.1% (Poland, 2018–2022); >80% (international internet survey, n=2,301) 36.9% cited "own decision" (Poland; multiple answers allowed) 64% cited a doctor's recommendation (Poland); doctors recommended it to 55.4% of all treated patients Galus 2022; MS supplement patterns 2011; MS comprehensive review[6][7][8][9]
Pregnancy Mostly 400 IU/day in prenatal vitamins; some 1,000–2,000 IU 71.7% used a vitamin D-containing supplement (US NHANES 1999–2014); 66.8% of lactating women Not reported for vitamin D; 16.1% of all pregnant women used supplements on their own decision About two-thirds of pregnant supplement users took at least one product on a provider's recommendation (all supplements, 2007–2014) Jun 2020 Obstet Gynecol; NASEM presentation[10][11]
Breast cancer survivors (including on aromatase inhibitors) Often >1,200 IU/day; trials up to 50,000 IU/week 75% (US, n=1,271); 61% (US lifestyle trials 2010–2017); 73% (Poland 2023–24); 61% of aromatase inhibitor users had a vitamin D prescription claim (Ireland, 2009) About 56% of users (estimate from Poland: 32.5% of survivors physician-advised vs 73% using) About 44% of users physician-advised (Poland, estimate); prescription-claim data only in Ireland Breast cancer DS use (J Nutr); Mikołajczyk 2026; Ireland PCRS 2018[12][13][14][15][16]
Osteoporosis (especially starting bisphosphonates) 400–1,000 IU/day usually with calcium; higher if deficient 77% co-prescribed calcium and/or vitamin D, 81.7% with bisphosphonates (France, MENOPOST); 95% calcium or vitamin D, self-report (US primary care, 2013) Not reported; in the US much is over the counter, and patient reports matched physician records for vitamin D only 53% of the time 77–82% co-prescribed (France); GPs wrote 66.9% of initial supplement prescriptions[17] MENOPOST; US primary care survey 2013[18]
Post-bariatric surgery Typically 1,000–3,000 IU/day (bariatric multivitamin plus Ca-D) Almost all start; about 60% adherent at 2 years (Sweden); about 50% at 1 year; about 92.6% use some supplement (Netherlands) About 10% used non-prescribed complete bariatric supplements (Sweden, year 1) Most (prescribed/recommended as standard protocol); exact % not reported Sweden 2-year cohort; Frontiers 2024; Adolescent bariatric study[19][20][21]
Nursing home residents (borderline) 800–1,000 IU/day (Denmark recommends 20 µg = 800 IU) 45% → 78% after quality improvement (Denmark); 47.1% at ≥800 IU (Australia, 2014) "Few" bought it themselves (Denmark) Most; Danish homes cite missing GP prescription as the main barrier Denmark quasi-experimental 2024; Denmark survey 2022; Australia 2017[22][23][24][25][26]

Published data show a clear majority of patients taking vitamin D in seven groups: chronic hypoparathyroidism (about 90%, on prescription active vitamin D), multiple sclerosis (about 66–80%), pregnancy (about 72% in the US, mostly through prenatal vitamins), breast cancer survivors (about 61–75%), patients starting osteoporosis drugs (about 77–82% co-prescribed in France), patients after bariatric surgery (most start; about 50–60% still take it at 1–2 years), and hemodialysis patients (55% overall in the international DOPPS study by Komaba et al., JBMR 2023, ranging from 25% in France to 72% in Sweden; about 66–84% in the US). Whether the patient or the doctor drives this depends mainly on the drug form. Active forms such as calcitriol, alfacalcidol and paricalcitol are prescription drugs. Plain vitamin D3 is mostly self-bought in the US but often prescribed in Europe. Only two of these groups have a published self-versus-doctor split specific to vitamin D: MS and breast cancer survivors (both from Poland).

TL;DR

  • Majority conditions: hypoparathyroidism (~91%), multiple sclerosis (~66–80%), pregnancy (~72%, US), breast cancer survivors (~61–75%), osteoporosis on treatment (~77–82% co-prescribed, France), post-bariatric surgery (most start; ~50–60% at 1–2 years) and hemodialysis (55% active vitamin D in the international DOPPS study, Komaba et al. 2023; higher in the US).
  • Who decides: in hypoparathyroidism and dialysis, essentially all use is doctor-prescribed, because active vitamin D is prescription-only. In MS (Poland; Galus et al., J Clin Med 2022, Medical University of Silesia), 64% of users cited a doctor's recommendation and 36.9% their own decision; respondents could give more than one reason. Among breast cancer survivors in Poland, roughly 44% of users had been told by a physician to take it; the rest were mostly self-initiated. In US pregnancy, Jun et al. (Obstet Gynecol 2020, NHANES 2007–2014) found that about two-thirds of pregnant supplement users took at least one product on a provider's recommendation.
  • The split is rarely reported. For US adults in general, Bailey et al. (JAMA Intern Med 2013, NHANES 2007–2010) found that only 23% of all supplement products were taken on a provider's recommendation and 77% by personal choice, but for older Americans over half of vitamin D-only products were. Use is below 50% in IBD, hip fracture, long-term glucocorticoid users and US breastfed infants, even though guidelines recommend it.

Details

Prescription-driven conditions (active vitamin D). In chronic hypoparathyroidism, conventional therapy is calcium plus calcitriol or alfacalcidol.[27] In the PARADIGHM registry, 971 of 1,070 patients (90.7%) took one of these.[2] In Italian real-world data, two-thirds of treated patients took 0–0.99 µg/day of calcitriol.[28] Guideline doses run from 0.25 to 2.0 µg/day.[1] In dialysis, use is high but varies by country: Komaba et al. (JBMR 2023, DOPPS phases 3–6) found 55% of 41,677 hemodialysis patients were prescribed active vitamin D at enrollment (35% orally, 21% intravenously), highest in Sweden (72%) and Japan (63%) and lowest in France (25%) and Belgium (35%); the earlier DOPPS III phase (2005–06) reported 33% in France, 39% in Japan and 66% in the US. A US cohort found 83.9% treated with some vitamin D formulation in 2008.[5] Current KDIGO guidance suggests active vitamin D only for elevated or rising PTH, which helps explain why use is lower outside the US.[29][30] In both conditions, prescribing is effectively 100%, because these are prescription drugs given by specialists or dialysis units.

MS: the clearest case of mixed patient- and doctor-driven use. MS patients take vitamin D far more than the general population.[8] The Polish study is the only one found that splits use by reason. Of the 74.1% using it, Galus et al. (J Clin Med 2022, Medical University of Silesia, 2018–2022) found 64% cited a doctor's recommendation, 36.9% their own decision and 21.55% concern about vitamin D deficiency. Medical records held a written recommendation in only 46.04% of cases, and "no doctor's recommendation" was the most common reason for not taking it. The authors note that the rate may be inflated at their center, which had run earlier vitamin D studies.[9] Doses are typically 2,000–5,000 IU/day, well above general-population doses, even though trials show inconsistent clinical benefit.[6][7]

Pregnancy. In the US, about three-quarters of pregnant women take a supplement, and 71.7% take one containing vitamin D, mostly prenatal vitamins at about 400 IU.[10][11] Jun et al. (Obstet Gynecol 2020, NHANES 2007–2014) found that about two-thirds of pregnant supplement users took at least one product on a provider's recommendation; overall, 47.4% of all pregnant women took a supplement on a provider's recommendation and 16.1% on their own decision. This figure covers all supplements, not vitamin D alone, so the doctor-driven share for vitamin D is an inference.

Breast cancer survivors. Vitamin D is now the most-used supplement in this group: 75% in a US cohort of 1,271 women, up from 44% in a 2014 study.[13] The Polish survivor survey suggests most of this use is self-initiated. Only 32.5% of breast cancer survivors had been told to take it by a physician, against 73% taking it, and only 39.5% of users said their oncology physician knew.[12][31] In Ireland, where prescription claims are recorded, 61% of aromatase-inhibitor users had a vitamin D claim in 2009.[16] That rate rose sharply after aromatase inhibitors came into use, which is consistent with prescribing to protect bone.[32]

What "majority" means here. A condition is counted as majority when at least one reasonably sized, recent study found more than 50% current use among diagnosed patients. Rates vary widely by country, care setting and year, so ranges are given.

Caveats

  • Country matters. In the US, vitamin D is mostly bought over the counter. Bailey et al. (JAMA Intern Med 2013, NHANES 2007–2010) found only 23% of all supplement products were used on a provider's recommendation and 77% by personal choice, although over half of vitamin D-only products used by adults over 60 were used on a provider's recommendation. In France, Ireland, Denmark and Finland, prescription or claims data capture much more of the use. Self-bought vitamin D is invisible in those registries, so registry figures understate total use.
  • The self-versus-doctor split is rarely measured for vitamin D. Only the MS (Poland) and cancer-survivor (Poland) studies report it directly. Values labeled "estimate" are inferred from drug status (prescription-only active forms) or from denominators within the same study. The NHANES pregnancy and all-adult figures cover all supplements. Where sources separate the two, "recommended" (advice) differs from "prescribed" (a written prescription or claim). The Polish MS figure is a recommendation, while the French and Irish figures are prescriptions or claims.
  • Self-report is unreliable. In a US primary care study, patient reports and physician records agreed on vitamin D use only 53% of the time.[18]
  • Adherence drops over time. Bariatric and hip-fracture cohorts show large drops in use within 6–12 months.[21][33]
  • Several studies are older (2011–2014) or single-center, and may not reflect 2026 practice.

Common, but under 50% (for context):

  • Inflammatory bowel disease: 41% prescribed (US VA, n=5,021); about 30% (Germany).[34][35][36]
  • Hip fracture patients: 19% before the fracture, 27% at discharge, 21% at 12 months (n=1,090). About 36.7% persist at 6 months even when prescribed to all (Italy).[33][37]
  • Long-term oral glucocorticoid users: 18.5% vitamin D (US NHANES 1999–2008); 46.6% prescribed calcium plus vitamin D (UK polymyalgia rheumatica cohort); 55% calcium and/or vitamin D among high-risk users (France, 2017).[38][39][40]
  • Breastfed infants: only 20.5% got the recommended 400 IU (US NHANES 2009–2016), and 24.3% of breast-milk-fed infants took any vitamin D supplement. Quebec reported 58.1%, so this may cross 50% in Canada.[41][42][43]
  • Adults with cystic fibrosis: 47.6% reported specific vitamin D use (adult cohort), though most also take CF-specific ADEK multivitamins, so total exposure is probably higher.[44]
  • Older adults in general (US): vitamin D is the most-used single supplement in US adults aged 50 and over, at 37.4% (Health and Retirement Study, J Nutr Health Aging 2022). Adding calcium-plus-D and multivitamins brings total exposure close to or above half, depending on definition.
  • Conditions with no reliable patient-population usage data found in this review include RA, lupus, psoriasis, depression, diabetes, heart failure, autism and long COVID. No majority claim can be made for them.

Recommendations

  • If your question is "who decides": treat hypoparathyroidism and dialysis as doctor-driven, MS and breast cancer as mixed (roughly half to two-thirds doctor-influenced), and US pregnancy and general adult use as mostly self-initiated or OTC, with a prenatal-care nudge.
  • For a definitive split in your own country, the best design is to link prescription registries (e.g., Scandinavian registries, CPRD) with survey data on the same patients. No published study has done this across conditions.

Sources

  1. Treatment options in hypoparathyroidism - PMC - NIH
  2. Health-related quality of life in a cohort of 1070 patients with hypoparathyroidism - PMC
  3. Active Vitamin D Use and Fractures in Hemodialysis Patients: Results from the International DOPPS
  4. Assessing the effect of oral activated vitamin D on overall survival in hemodialysis patients: a landmark analysis - PMC
  5. Full article: Trends and Variations in Intravenous Vitamin D Use among Hemodialysis Patients in the United States
  6. Vitamin D Supplementation Practices among Multiple Sclerosis Patients and Professionals
  7. Vitamin D and Multiple Sclerosis: A Comprehensive Review - PMC
  8. Patterns of dietary and herbal supplement use by multiple sclerosis patients - PubMed
  9. Vitamin D Supplementation Practices among Multiple Sclerosis Patients and Professionals
  10. Dietary Supplement Use and Its Micronutrient... : Obstetrics & Gynecology
  11. DIETARY SUPPLEMENT USE AND ITS MICRONUTRIENT ...
  12. Vitamin D-Related Information Exposure, Attitudes, and Practices Among Prostate and Breast Cancer Survivors in Poland: Implications for Patient–Physician Communication
  13. Dietary Supplement Use in Women Diagnosed with Breast Cancer - ScienceDirect
  14. Dietary Supplement Use and Interactions with Tamoxifen and Aromatase Inhibitors in Breast Cancer Survivors Enrolled in Lifestyle Interventions
  15. Vitamin D: Are We Ready to Supplement for Breast Cancer Prevention and Treatment? - Crew - 2013 - International Scholarly Research Notices - Wiley Online Library
  16. Trends in vitamin D supplement use in a general female and breast cancer population in Ireland: A repeated cross-sectional study - PMC
  17. MENOPOST - Calcium and vitamin D supplementation in postmenopausal osteoporosis treatment: a descriptive cohort study
  18. Overuse and underuse of calcium and vitamin D in women with osteoporosis: A survey in a primary care setting
  19. Adherence to vitamin and mineral supplementation after bariatric surgery
  20. Frontiers
  21. Adherence to Vitamin Supplementation Recommendations in Youth Who Have Undergone Bariatric Surgery as Teenagers: a Mixed Methods Study - PMC
  22. Prevalence of vitamin D supplement use in Australian residential aged care facilities in November 2014
  23. (PDF) Adherence and barriers to the vitamin D and calcium supplement recommendation at Danish nursing homes: a cross-sectional study
  24. Vitamin D Status and Physical Functioning in Nursing Home Residents after Improved Adherence to the Vitamin D and Calcium Recommendation-A Quasiexperimental Study - PubMed
  25. Vitamin D and Calcium Supplementation at Danish Nursing Homes
  26. Vitamin D Status and Physical Functioning in Nursing Home Residents after Improved Adherence to the Vitamin D and Calcium Recommendation—A Quasiexperimental Study
  27. UK national chronic hypoparathyroidism audit - PMC
  28. Hypoparathyroidism: clinical profiles, healthcare use, and costs from real-world data from Italy - PMC
  29. Active Vitamin D Use and Fractures in Hemodialysis Patients : Results from the International DOPPS
  30. Active Vitamin D Use and Fractures in Hemodialysis Patients: Results from the International DOPPS - Komaba - 2023 - Journal of Bone and Mineral Research - Wiley Online Library
  31. Vitamin D-Related Information Exposure, Attitudes, and Practices Among Prostate and Breast Cancer Survivors in Poland: Implications for Patient–Physician Communication
  32. Trends in vitamin D supplement use in a general female and breast cancer population in Ireland: A repeated cross-sectional study
  33. Persistence with calcium and vitamin D in elderly patients after hip fracture
  34. Utilization of Preventive Measures for Glucocorticoid-Induced Osteoporosis among Veterans with Inflammatory Bowel Disease - PMC
  35. High Prevalence of Vitamin D Deficiency among Patients with Inflammatory Bowel Disease - PMC
  36. The Real-World Impact of Vitamin D Supplementation on Inflammatory Bowel Disease Clinical Outcomes - PMC
  37. Before and after hip fracture, vitamin D deficiency may not be treated sufficiently - PubMed
  38. Nationwide prevalence of glucocorticoid prescriptions over 17 years and osteoporosis prevention among long-term users - Hulda Hrund Bjornsdottir, Ólafur Brynjólfur Einarsson, Gerdur Gröndal, Bjorn Gudbjornsson, 2024
  39. Prevalence of oral glucocorticoid usage in the United States: A general population perspective
  40. Fragility fractures and prescriptions of medications for osteoporosis in patients with polymyalgia rheumatica: results from the PMR Cohort Study
  41. Vitamin D - Health Professional Fact Sheet
  42. Study Comparing Two Vitamin D Supplements for Infants: Liquid Versus D-Strips
  43. Dietary Supplement Use among Infants and Toddlers Aged <24 Months in the United States, NHANES 2007–2014 - PMC
  44. Vitamin D and bone health in adults with cystic fibrosis - PMC

Unfortunately, often not start treatment with a loading dose, too little, too late, wrong form, or without cofactors

Loading dose

Form (Sublingual nanoemulsion - hours)

Need 40-100 ng (depends on the health problem)

Vitamin D treatment in VitaminDWiki

Form

Cofactors

Vitamin D Proofs

Some items from Breast cancer treatments now often include Vitamin D